细胞周期蛋白依赖性激酶抑制剂  

Cyclin-dependent kinase inhibitor: novel approaches for cancer therapy

作　　者：罗蕴[1] 胡永洲[1] 

机构地区：[1]浙江大学药学院药物研究所,杭州310006

出　　处：《中国现代应用药学》2003年第5期360-363,共4页Chinese Journal of Modern Applied Pharmacy

摘　　要：目的　系统介绍细胞周期蛋白依赖性激酶 (CDK)抑制剂的抗肿瘤作用。方法　对近几年国外有关CDK抑制剂的发现、构效研究及临床试验等文献进行检索和综述。结果　olomoucine,roscovitine等三取代嘌呤类化合物 ,flavopiridol及butyrolac tone三类化合物具有明显的CDK抑制活性 ,对多种人类肿瘤均有疗效 ,且不良反应小。结论　细胞周期蛋白依赖性激酶(CDK)OBJECTIVE To systematically introduce the anticancer function of cyclin dependent kinase inhibitor. METHOD Consulting the literature both in domestic and foreign, the development and action mechanism study of CDKs inhibitors were reviewed.RESULTS There are three classes of CDK inhibitors that show strong specificity for CDKs: purine based compound olomoucine and its analogues, flavopiridol and butyrolactone.CONCLUSION The rapid development of CDK inhibitors must be just around the corner.

关 键 词：细胞周期 细胞周期蛋白依赖性激酶抑制剂 肿瘤治疗olomoucine ROSCOVITINE FLAVOPIRIDOL BUTYROLACTONE 

分 类 号：R917.796[医药卫生—药物分析学] R979.1[医药卫生—药学]